Completed PHASE2 INTERVENTIONAL 4-arm NCT04120116

FX-322 in Adults With Stable Sensorineural Hearing Loss

A Phase 2a, Prospective, Randomized, Double-Blind, Placebo-Controlled, Single and Repeat-Dose, Multicenter, Exploratory Efficacy Study of FX-322 Administered by Intratympanic Injection in Adults With Stable Sensorineural Hearing Loss

Sponsor: Frequency Therapeutics

Conditions Noise Induced Hearing Loss Sensorineural Hearing Loss Sudden Sensorineural Hearing Loss

Interventions FX-322 (Four Doses) FX-322 (One Dose) FX-322 (Two Doses) Placebo

Updated 13 times since 2019 Last updated: Apr 25, 2023 Started: Oct 4, 2019 Primary completion: Oct 6, 2020 Completion: Dec 17, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Noise Induced Hearing Loss and Sensorineural Hearing Loss and is currently completed. Frequency Therapeutics leads this study, which shows 13 recorded versions since 2019 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

13 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
May 2023 — Jul 2024 [monthly]

Completed PHASE2
Apr 2023 — May 2023 [monthly]

Completed PHASE2
Nov 2022 — Apr 2023 [monthly]

Completed PHASE2

▶ Show 8 earlier versions

Apr 2022 — Nov 2022 [monthly]

Completed PHASE2
Nov 2021 — Apr 2022 [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed
Jan 2021 — Nov 2021 [monthly]

Active Not Recruiting PHASE2
Nov 2020 — Jan 2021 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
May 2020 — Nov 2020 [monthly]

Recruiting PHASE2
Apr 2020 — May 2020 [monthly]

Recruiting PHASE2
Feb 2020 — Apr 2020 [monthly]

Recruiting PHASE2
Nov 2019 — Feb 2020 [monthly]

Recruiting PHASE2

First recorded

Oct 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Frequency Therapeutics

Data source: Frequency Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amherst, United States , Austin, United States , Boca Raton, United States , Colorado Springs, United States , Fresno, United States , Louisville, United States , Matthews, United States , Omaha, United States , Orangeburg, United States , Richmond, United States and 5 more locations